CA
NZ
UK
AU
IND
US
Septerna reported an EPS of $-0.29, marking a significant improvement compared to the consensus estimate of $-0.43. The upbeat performance in earnings highlights the company's potential, which may attract more investors looking for growth opportunities.
TELA Bio, Inc. posted a significant net loss of $11.3 million for the second quarter of 2026, falling short of the $-0.20Earnings Per Shareconsensus estimate due to weakened performance in its OviTex products. This dip comes as TELA's revenue has decreased by 4% year-over-year …
Vera Therapeutics reported a $109.5 million loss in the second quarter, which starkly contrasts with the smaller $76.5 million loss recorded in the same quarter the previous year. EPS figures for the last quarter ending March 31 fell short of projections, with a reported …
During this period, Palisade Bio's earnings per share were $-0.05, aligning with analysts' expectations, demonstrating stability even amid operational losses. The company’s cash position remains strong, with $125.2 million held, suggesting adequate funding for upcoming milestones. Shares are up 7.1% over the past month, …
Sana Biotechnology, Inc. (NASDAQ: SANA) announced a second-quarter earnings per share (EPS) of $-0.13, which is better than the expected $-0.15 from analysts. The performance reflects strategic management of operational costs and bolsteringInvestmentin research and development. The share price is currently down 13.8% year-to-date …
Tactile Systems (NASDAQ: TCMD) reported first‑half 2026Revenueof $161 million. Revenue for the second quarter also reflects positive trends, contributing to increased investor confidence and a strong market outlook.
U.S. Physical Therapy, Inc. (NYSE: USPH) achieved total revenue of $214 million for the second quarter of 2026, reflecting an 8.5% growth compared to the prior year. The company experienced strong operational dynamics, driven by a notable increase in clinic visit volumes. In a …
The company's net loss for the quarter amounted to $63.2 million, up from $43.8 million in the same quarter last year. This increase highlights the growing costs associated with clinical development, raising concerns for investors regarding the company's financial health and future profitability as …
QuidelOrtho (NASDAQ: QDEL) nudged up 0.6% to $12.36 in early trading, a small lift that barely budges the stock from a 57.3% year‑to‑date slide. The modest rise arrives as the company sits with a marketCapitalizationof roughly $1.1 billion, far below its 52‑week peak of …
Envoy Medical's revenue figure indicates continued challenges for the company as it seeks to deliver on its innovative promises and achieve regulatory approval for its Acclaim cochlear implant. The reported revenue indicates continued challenges for Envoy Medical as it seeks to deliver on its …
Please wait processing your request...